Huda S. Salman

Hematology
720 Eskenazi Ave
Indianapolis, IN 46202

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.

B Cell Aplasia Following CAR T Cell Therapy: Incidence, Kinetics, Prognostic Implications, and Clinical Management.

Journal: Cancers
Published: June 29, 2026

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 13, 2024

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.

Journal: NPJ precision oncology
Published: November 12, 2024

CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.

CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: November 05, 2024

Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

Journal: Cancers
Published: July 26, 2024

Engineering resilient CAR T cells for immunosuppressive environment.

Engineering resilient CAR T cells for immunosuppressive environment.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 14, 2024

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.

Journal: Cancer discovery
Published: June 10, 2024

Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.

Targeting Interleukin-13 Receptor α2 and EphA2 in Aggressive Breast Cancer Subtypes with Special References to Chimeric Antigen Receptor T-Cell Therapy.

Journal: International journal of molecular sciences
Published: March 15, 2024

A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma.

A nontandem novel compound chimeric antigen receptor redirected to target CD20-CD19 positive B-cell acute leukemias and B-cell lymphoma.

Journal: Clinical and translational medicine
Published: March 07, 2024

Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?

Harnessing the Potential of Chimeric Antigen Receptor T-Cell Therapy for the Treatment of T-Cell Malignancies: A Dare or Double Dare?

Journal: Cells
Published: November 16, 2022

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.

Journal: The Lancet. Oncology
Published: January 19, 2022

Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment.

Sphingolipids in Hematopoiesis: Exploring Their Role in Lineage Commitment.

Journal: Cells
Published: July 29, 2021
Showing 1-12 of 31

Last Updated: 09/26/2026